Join Growin Stock Community!

Aethlon medical, inc.AEMD.US Overview

US StockHealthcare
(No presentation for AEMD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AEMD AI Insights

AEMD Overall Performance

AEMD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AEMD Recent Performance

-5.81%

Aethlon medical, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

AEMD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AEMD Key Information

AEMD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AEMD Profile

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

Price of AEMD

AEMD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AEMD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.14
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.37
PB Ratio
0.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-15.14
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.37
PB Ratio
0.39
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is AEMD's latest earnings report released?

    The most recent financial report for Aethlon medical, inc. (AEMD) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AEMD's short-term business performance and financial health. For the latest updates on AEMD's earnings releases, visit this page regularly.

  • How much debt does AEMD have?

    As of the end of the reporting period, Aethlon medical, inc. (AEMD) had total debt of 417.52K, with a debt ratio of 0.05. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does AEMD have?

    At the end of the period, Aethlon medical, inc. (AEMD) held Total Cash and Cash Equivalents of 7.06M, accounting for 0.88 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AEMD's EPS continuing to grow?

    According to the past four quarterly reports, Aethlon medical, inc. (AEMD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.45. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AEMD?

    Aethlon medical, inc. (AEMD)'s Free Cash Flow (FCF) for the period is -1.87M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AEMD?

    The latest valuation data shows Aethlon medical, inc. (AEMD) has a Price-To-Earnings (PE) ratio of -0.23 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.